The British pharmaceutical giant GlaxoSmithKline (NYSE: GSK) seemingly defied gravity last month by gaining a noteworthy 8.33%, according to data from S&P Global Market Intelligence.
The British pharmaceutical giant GlaxoSmithKline (NYSE: GSK) seemingly defied gravity last month by gaining a noteworthy 8.33%, according to data from S&P Global Market Intelligence.